Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly & Co. said it expects to generate adjusted 2025 profit of $22.50 a share to $24 a share in 2025. That compares to the FactSet consensus estimate of $22.76 a share for 2025.

Lily Graves thought her high school career was over two weeks ago. She returned Tuesday to help lead Franklin Central to the ...

The “Emily in Paris” star and her husband, Charlie McDowell, welcomed their first child via surrogate in January.

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

Grant support was also obtained from Eli Lilly, Inc. The following represents disclosure information ... Relationships may not relate to the subject matter of this manuscript. For more information ...

Lily Allen has admitted that she “could be ... Allen has since been replaced on the podcast by temporary co-host Mabel. Rizzle Kicks‘ Jordan Stephens and comedian Simon Amstell will then ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

more patients now have a treatment option that may provide long-term disease control and address key symptoms that matter most to them, reflecting Lilly’s ongoing commitment to elevate care and ...

The FDA ap­proved Eli Lil­ly’s Omvoh in Crohn’s dis­ease, the com­pa­ny an­nounced Wednes­day, hand­ing the drug its sec­ond in­di­ca­tion af­ter giv­ing it a green light … ...

Quarterback Jordan Love, who threw 11 interceptions in his first eight ... We’re in every game — no matter how much we mess up or how many mistakes we have (or) how slow we start. “We’ve got to learn ...

Eli Lilly still looks poised to hit the $1 trillion market cap in the future, and I think it's just a matter of when rather than if it will happen. And that's why it can still make for a good buy ...